

+

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete if Known**

**SUPPLEMENTAL  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

<b>Application Number</b>	10/040,010
<b>Filing Date</b>	January 4, 2002
<b>First Named Inventor</b>	Thomas M. Mills
<b>Group Art Unit</b>	1614
<b>Examiner Name</b>	Unknown
<b>Attorney Docket Number</b>	M0351-267875
<b>Express Mail Certificate</b>	EV 032 110 529 US

U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature		Date Considered	1/15/04
-----------------------	---	--------------------	---------

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete if Known**

*(use as many sheets as necessary)*

Sheet 2 of 2

Application Number
Filing Date
First Named Inventor
Group Art Unit
Examiner Name
Attorney Docket Number

RECEIVED  
OCT 10 2002  
TECH CENTER 1000/2900

[illegible]

**Examiner  
Signature**

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

M0351-267875  
WINLIB01:968574.1

Please type a plus sign (+) inside this box



Approved for use through 10/31/2003 DMB 0651-003  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 10-9APTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 4

## Complete if Known

Application Number 10/040,010  
Filing Date January 4, 2002  
First Named Inventor Mills, T. M. et al.  
Group Art Unit Unassigned  
Examiner Name Unassigned  
Attorney Docket Number M0351-267875

Express Mail Certificate EV 032 197 074 US

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
SAO	1	4,127,118		Latorre, Alvaro	11-28-78	
	2	4,801,587		Voss, Gene et al.	01-31-89	
	3	4,968,679		Bodo Junge, Wuppertal et al.	11-06-90	
	4	5,059,603		Rubin, David	10-22-91	
	5	5,242,391		Place, V. A. et al.	09-07-93	
	6	5,256,652		El-Rashidy, Ragab	10-26-93	
	7	5,888,534		El-Rashidy, Ragab et al.	03-30-99	
	8	5,945,117		El-Rashidy, Ragab et al.	08-31-99	
	9	5,981,563		Lowrey, Fred	11-09-99	
	10	6,007,824		Duckett, M. J. et al.	12-28-99	
	11	6,051,594		Lowrey, Fred	04-18-00	
	12	6,087,362		El-Rashidy, Ragab	07-11-00	
	13	6,093,181		Place, V. A. et al.	07-25-00	
	14	6,100,270		Campbell, S. F.	08-08-00	
	15	6,100,286		Lowrey, Fred	08-08-00	
	16	6,124,337		Lowrey, Fred	09-26-00	
	17	6,166,061		Lowrey, Fred	12-26-00	
	18	6,239,117 B1		Christ, G. J. et al.	05-29-01	
	19	6,266,560 B1		Zhang, L. et al.	07-24-01	

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>3</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>2</sup> (if known)				
SAO	20	BG	103246A (abstract translation)		Yoshitomi Pharmaceu- tical Industries Ltd.	05-31-00		✓
	21	EP	0633023A1		Eli Lilly & Co.	01-11-95		✓
	22	JP	7048254 (abstract translation)		Eli Lilly & Co.	02-21-95		✓
	23	WO	98/06433 (abstract translation)		Yoshitomi Pharmaceu- tical Industries Ltd.	02-19-98		✓
	24	WO	00/33845 (abstract translation)		Yoshitomi Pharmaceu- tical Industries Ltd.	06-15-00		✓
Examiner Signature		Date Considered				4/15/04		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box

+

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid data control number

Approved for use through 10/31/2002 OMB 0651-0831  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A-PTB

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 4

## Complete if Known

Application Number	10/040,010
Filing Date	January 4, 2002
First Named Inventor	Mills, T. M. et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	M0351-267875

## OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
SAD	25	AMANO, M., et al., Phosphorylation and Activation of Myosin by Rho-associated Kinase (Rho-kinase), <i>J. Biol. Chem.</i> , <b>271</b> , 20246-20249, 1996	✓
	26	ANDERSSON, K.E., Pharmacology of Penile Erection, <i>Pharmacol. Rev.</i> , <b>53</b> , 417-450, September 2001	✓
	27	APENSTROM, P., Effectors for the RHO GTPases, <i>Curr. Opin. Cell. Biol.</i> , <b>11</b> , 95-102, 1999	✓
	28	BERMAN, J.R., et al., Anatomy and Physiology of Female Sexual Function and Dysfunction, <i>Eur. Urology</i> <b>38</b> , 20-29, 2000	✓
	29	BIVALACQUA, T.J., et al., Adenoviral gene transfer of endothelial nitric oxide synthase (eNOS) to the penis improves age-related erectile dysfunction in the rat, <i>Int. J. Impotence Res.</i> , <b>12</b> , S8-S17, September 2000	✓
	30	BURNETT, A.L., Role of Nitric Oxide in the Physiology of Erection, <i>Biol. Reprod.</i> , <b>52</b> , 485-489, 1995	✓
	31	CHAMPION, H.C., et al., Gene transfer of endothelial nitric oxide synthase to the penis augments erectile responses in the aged rat, <i>Proc. Natl. Acad. Sci., USA</i> , <b>96</b> , 11648-11652, 1999	✓
	32	CHITALEY, K., et al., Antagonism of Rho-kinase stimulates rate penile erection via nitric oxide-independent pathway, <i>Nature Med.</i> , <b>7</b> , 119-122, January 2001	✓
	33	CHITALEY, K., et al., RhoA/Rho-kinase: a novel player in the regulation of penile erection, <i>Int'l J. of Impotence Research</i> , <b>13</b> , 67-72, April 2001	✓
	34	CHITALEY, K., et al., Decreased penile erection in DOCA-salt and stroke prone-spontaneously hypertensive rats, <i>Int'l J. of Impotence Research</i> , <b>13</b> , Suppl 5, S16-S20, December 2001	✓
	35	CHRIST, G.J., et al., The application of gene therapy to the treatment of erectile dysfunction, <i>Int. J. Impotence Res.</i> , <b>10</b> , 111-112, 1998	✓
	36	CHRIST, G. J., et al., Intracorporal injection of <i>hSlo</i> cDNA in rats produces physiologically relevant alterations in penile function, <i>Am. J. Physiol.</i> , <b>275</b> , H600-608, 1998	✓
	37	DAI, Y., et al., Receptor-specific influence of endothelin-1 in the erectile response of the rat, <i>Am. J. Physiol. Regulatory Integrative Compl. Physiol.</i> , <b>279</b> , R25-R30, July 2000	✓
	38	DiSALVO, J., et al., Vanadate-Induced Contraction of Smooth Muscle and Enhanced Protein Tyrosine Phosphorylation, <i>Arch. Biochem. Biophys.</i> , <b>304</b> , 386-391, 1993	✓
	39	DUCKERS, H.J., et al., Heme oxygenase-1 protects against vascular constriction and proliferation, <i>Nature Med.</i> , <b>7</b> , 693-698, June 2001	✓
	40	FENG, et al., Rho-associated Kinase of Chicken Gizzard Smooth Muscle, <i>J. Biol Chem.</i> , <b>274</b> , 3744-3752, 1999	✓
	41	GARBAN, H., et al., Cloning of Rat and Human Inducible Penile Nitric Oxide Synthase. Application for Gene Therapy of Erectile Dysfunction, <i>Biol. Reprod.</i> , <b>56</b> , 954-963, 1997	✓
SAD	42	ISHIZAKI, T., et al., Pharmacological Properties of Y-27632, a Specific	✓

SAD 1/15/04

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449APT

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 4

Complete if Known

Application Number	10/040,010
Filing Date	January 4, 2002
First Named Inventor	Mills, T. M. et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	M0351-267875

RECEIVED  
JUL 8 2002  
TECH CENTER 1800/1900

390		Inhibitor of Rho-associated Kinases, <i>Mol. Pharmacol.</i> , <b>57</b> , 976-983, May 2000	
	43	JAROW, I.P., et al., Clinical Efficacy of Sildenafil Citrate Based on Etiology and Response to Prior Treatment <i>J. Urology</i> <b>162</b> , 722-725, 1999	✓
	44	KIMURA, K., et al., Regulation of Myosin Phosphatase by Rho and Rho-Associated Kinase (Rho-Kinase), <i>Science</i> , <b>273</b> , 245-248, 1997	✓
	45	KUREISHI, Y., et al., Rho-associated Kinase Directly Induces Smooth Muscle Contraction through Myosin Light Chain Phosphorylation, <i>J. Biol. Chem.</i> , <b>272</b> , 12257-12260, 1997	✓
	46	LOWRY, O.H., et al., Protein Measurement with the Folin Phenol Reagent, <i>J. Biol. Chem.</i> , <b>193</b> , 265-275, 1951	✓
	47	MILLS, T., et al., Androgen Maintenance of Erectile Function in the Rat Penis, <i>Biol. Reprod.</i> , <b>46</b> , 342-348, 1992	✓
	48	MILLS, T., et al., Effects of Castration and Androgen Replacement on the Hemodynamics of Penile Erection in the Rat, <i>Biol. Reprod.</i> , <b>51</b> , 234-238, 1994	✓
	49	MILLS, T., et al., Androgenic Maintenance of the Erectile Response in the Rat, <i>Steroids</i> , <b>64</b> , 605-609, 1999	✓
	50	MILLS, T., et al., Androgenic Maintenance of Inflow and Veno-Occlusion during Erection in the Rat, <i>Biol. Reprod.</i> , <b>59</b> , 1413-1418, 1998	✓
	51	MILLS, T., et al., The Effect of an Inhibitor of Rho Kinase on the Erectile Response, <i>Int'l J. of Impotence Research</i> , Suppl 3, Abstract A1, September 2000	✓
	52	MILLS, T., et al., Inhibition of the Rho Kinase Pathway Leads to Penile Erection, <i>9<sup>th</sup> World Meeting on Impotence Research</i> , Perth Australia, Abstract P6, Nov. 26-30, 2000	✓
	53	MILLS, T., et al., Vasoconstrictors in erectile physiology, <i>Int'l J. of Impotence Research</i> , <b>13</b> , Suppl 5, S29-S34, December 2001	✓
	54	MILLS, T., et al., Effect of Rho-kinase inhibition on vasoconstriction in the penile circulation, <i>J. Appl. Physiol.</i> , <b>91</b> , 1269-1273, September 2001	✓
	55	MILLS, T., New Biochemical Pathway May Control Erection, <i>TheScientificWorld</i> , <b>1</b> , 184-185, May 2001	✓
	56	MOODY, J.A., et al., Effects of Long-Term Oral Administration of L-Arginine on the Rat Erectile Response, <i>J. Urology</i> , <b>158</b> , 942-947, 1997	✓
	57	OKAMURA, T., et al., Monkey corpus cavernosum relaxation mediated by NO and other relaxing factor derived from nerves, <i>Am J. Physiol.</i> , <b>274</b> , H1075-H1081, 1998	✓
	58	PFITZER, G., et al., Involvement of small GTPases in the regulation of smooth muscle contraction, <i>Acta Physiol. Scand.</i> , <b>164</b> , 449-456, 1998	✓
	59	REES, R. W., et al., Y-27632, an inhibitor of Rho-kinase, antagonizes noradrenergic contraction in the rabbit and human penile corpus cavernosum, <i>British J. of Pharmacology</i> , <b>133</b> , 455, June 2001	✓
	60	REES, R. W., et al., Human and rabbit cavernosal smooth muscle cells express Rho-kinase, <i>Int'l J. of Impotence Research</i> , <b>14</b> , 1-7, February 2002	✓
590	61	REILLY, C.M., et al., Androgens Modulate the $\alpha$ -Adrenergic Responsiveness of Vascular Smooth Muscle in the Corpus Cavernosum, <i>J.</i>	✓

590 1/13/04

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)  
Approved for use through 10/31/2002. OMB 055100031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449APTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 4

## Complete if Known

Application Number	10/040,010
Filing Date	January 4, 2002
First Named Inventor	Mills, T. M. et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	M0351-267875

RECEIVED  
JUL 8 0 2002  
TECH CENTER 1000/2900

SAG			of Andrology, 1, 26-31, 1997	
	62	REILLY, C.M., et al., Androgenic Regulation of NO Availability in Rat Penile Erection, <i>J. Andrology</i> , <b>18</b> , 110-115, 1997		✓
	63	REILLY, C.M., et al., Androgenic Maintenance of the Rat Erectile Response Via a Non-Nitric-Oxide-Dependent Pathway, <i>J. Andrology</i> , <b>18</b> , 588-594, 1997		✓
	64	RIDLEY, A., RHO: theme and variations, <i>Curr. Biol.</i> , <b>6</b> , 1256-1264, 1996		✓
	65	SAHAI, E., et al., RhoA effector mutants reveal distinct effector pathways for cytoskeletal reorganization, SRF activation and transformation, <i>EMBO J.</i> , <b>17</b> , 1350-1361, 1998		✓
	66	SAUZEAU, V., et al., Cyclic GMP-dependent Protein Kinase Signaling Pathway Inhibits RhoA-induced Ca <sup>2+</sup> Sensitization of Contraction in Vascular Smooth Muscle, <i>J. Biol. Chem.</i> , <b>275</b> , 21722-21729, July 2000		✓
	67	SAWADA, N., et al., cGMP-Dependent Protein Kinase Phosphorylates and Inactivates RhoA, <i>Biochem. Biophys. Res. Comm.</i> , <b>280</b> , 798-805, January 26, 2001		✓
	68	SCHOTT, E., et al., Expression of a recombinant preproendothelin-1 gene in arteries stimulates vascular contractility, <i>Am. J. Physiol.</i> , <b>272</b> , H2385-H2393, 1997		✓
	69	SOMLYO, A.P., et al., From pharmacomechanical coupling to G-proteins and myosin phosphatase, <i>Acta Physiol. Scand.</i> , <b>164</b> , 437-448, 1998		✓
	70	SOMLYO, et al., Signal transduction by G-proteins, Rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II, <i>J. Physiol.</i> , <b>522</b> , 177-185, January 2000		✓
	71	TRAISH, A., et al., Role of alpha adrenergic receptors in erectile function, <i>Int. J. Impot. Res.</i> , <b>12</b> , Suppl. 1, S48-63, March 2000		✓
	72	UEHATA, M., et al., Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension, <i>Nature</i> , <b>389</b> , 990-994, 1997		✓
	73	VIRAG R., Indications and Early Results of Sildenafil (VIAGRA) in Erectile Dysfunction, <i>Urology</i> <b>54</b> , 1073-77, 1999		✓
	74	WEBER, et al., Enhanced Relaxation to the Rho-Kinase Inhibitor Y-27632 in Mesenteric Arteries from Mineralocorticoid Hypertensive Rats, <i>Pharmacology</i> , <b>63</b> , 129-133, October 2001		✓
	75	WINGARD, C. J., et al., Recovery of Penile Erection by Inhibition of Rho-Kinase in a Castrate Rat Model of Erectile Dysfunction, <i>Int'l J. of Impotence Research</i> , <b>13</b> , Suppl 5, Abstract 1, December 2001		✓
SAG	76	WINGARD, C. J., et al., Erection and NO override the vasoconstrictive effect of alpha-adrenergic stimulation in the rat penile vasculature, <i>Int'l J. of Impotence Research</i> , <b>13</b> , 212-220, August 2001		✓
Examiner Signature	SAG		Date Considered	1/15/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

M0351-267875 WINLIB01:932491.1








+

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+



**2<sup>nd</sup> SUPPLEMENTAL  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Sheet	1	of	2
-------	---	----	---

Application Number	10/040,010
Filing Date	January 4, 2002
First Named Inventor	Thomas M. Mills
Group Art Unit	1617
Examiner Name	Hui, San Ming R.
Attorney Docket Number	M0351-267875 (011-00)
Express Mail Certificate	EV 127 539 264 US

[illegible][illegible]

*SAD*

1/15/04

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.

**DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

+